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Key questions
What is already known about this subject?
 ► In Fontan patients with atrial arrhythmias, non-vita-
min K antagonist oral anticoagulants (NOACs) have 
a class III recommendation according to the PACES/
HRS guideline in 2014, despite lack of data on out-
comes as opposed to evidence of harm.
What does this study add?
 ► This international multicentre prospective cohort 
study shows that NOACs seem to be well tolerated 
and have comparable efficacy and safety as vitamin 
K antagonists during short-term follow-up in adults 
with a Fontan circulation.
How might this impact on clinical practice?
 ► With growing evidence of efficacy and safety re-
sults with NOACs, future guidelines should reas-
sess NOACs as a treatment option for prevention of 
thromboembolism in Fontan patients.
AbstrAct
Background In Fontan patients with atrial arrhythmias 
(AA), non-vitamin K antagonist oral anticoagulants(NOACs) 
have a class III recommendation according to the Pediatric & 
Congenital Electrophysiology Society (PACES)/Heart Rhythm 
Society (HRS) guideline in 2014, due to lack of data on 
outcomes as opposed to evidence of harm. To address this 
gap in data, we investigated the safety and efficacy of NOACs 
in adults with a Fontan circulation in a worldwide study.
Methods This is an international multicentre prospective 
cohort study, using data from the NOTE (non-vitamin 
K antagonist oral anticoagulants for thromboembolic 
prevention in patients with congenital heart disease) registry. 
The study population comprised consecutive adults with a 
Fontan circulation using NOACs. Follow-up took place at 6 
months and yearly thereafter. The primary endpoints were 
thromboembolism and major bleeding. Secondary endpoint 
was minor bleeding.
Results From April 2014 onward, 74 patients (mean age 
32±10 years (range 18–68), 54% male) with a Fontan 
circulation using NOACs were included. During a median 
follow-up of 1.2 (IQR 0.8–2.0) years, three thromboembolic 
events (2.9 per 100 patient-years (95% CI 0.7 to 7.6)) and 
three major bleedings (2.9 per 100 patient-years (95% CI 0.7 
to 7.6)) occurred in five atriopulmonary Fontan and one total 
cavopulmonary connection Fontan patients with AA. Fifteen 
patients experienced minor bleeding episodes (15.8 per 100 
patient-years (95% CI 9.1 to 25.2)). In patients (n=37) using 
vitamin K antagonists (VKAs) prior to the initiation of NOAC, 
annual incidence of historical thromboembolic events and 
major bleeding were 2.4% (95% CI 0.4% to 7.4%) (n = 2) 
and 1.2% (95% CI 0.7% to 5.1%) (n = 1), respectively.
Conclusions In this review of the largest Fontan cohort 
using NOACs with prospective follow-up, NOACs appear to 
be well tolerated and their efficacy and safety during short-
term follow-up seem comparable to VKAs. Longer term data 
are required to confirm these promising short-term results.
IntRoduCtIon
Patients with a Fontan circulation have a 
paradoxical coexistence of an increased risk 
of thromboembolism as well as bleeding.1–3 
However, optimal thromboprophylaxis is 
unclear in this patient group due to limited 
evidence for efficacy and safety of antico-
agulation or antiplatelet treatment, mostly 
consisting of retrospective studies performed 
in children or mixed cohorts with adult 
patients.4–7 Furthermore, conventional throm-
boprophylaxis such as vitamin K antagonists 
(VKAs) and aspirin have important limitations 
since they are suboptimal with considerable 
residual thromboembolic risk of 9.8%–13%,3 
while there are difficulties achieving consistent 
international normalised ratio (INR) range 
with VKAs,4 and 52% of aspirin-treated Fontan 
adults having aspirin resistance.5 Also, pursuit 
of optimal thromboprophylaxis continues to 
be a growing concern as the numbers of adults 
with Fontan circulation are growing with future 
prospect of more than 50% of these patients 
 o
n
 15 July 2019 by guest. Protected by copyright.
http://openheart.bmj.com/
O
pen Heart: first published as 10.1136/openhrt-2018-000985 on 3 June 2019. Downloaded from
 
Open Heart
2 Yang H, et al. Open Heart 2019;6:e000985. doi:10.1136/openhrt-2018-000985
acquiring atrial arrhythmias (AA) at 20 years after a Fontan 
procedure.6
Non-vitamin K antagonist oral anticoagulants (NOACs) 
are an attractive alternative to VKAs with the potential for 
reduced intracerebral haemorrhage, relatively few dietary 
or drug interactions and no need for ongoing INR moni-
toring as a result of their predictable pharmacokinetics. 
However, in Fontan patients with AA, NOACs have a class 
III recommendation according to the recent PACES/
HRS guideline in 2014,7 due to lack of data on outcomes 
as opposed to evidence of harm. Hence, providers were 
initially wary of prescribing NOACs in this population due 
to concerns over lack of data to support efficacy and safety. 
However, in the course of time, despite the class III recom-
mendation, NOACs are increasingly being used in clinical 
practice. Therefore, there is growing need to obtain safety 
and efficacy data of NOACs in Fontan patients.
To address this gap in data and to monitor the applica-
tion of NOACs in daily clinical practice, we investigated 
the safety and efficacy of NOACs in adults with a Fontan 
circulation in a worldwide prospective observational 
study, by means of the NOTE registry: NOACs for throm-
boembolic prevention in patients with congenital heart 
disease.8
MateRIals and MetHods
study design and participants
NOTE is an ongoing international and multicentre prospec-
tive registry of adults with congenital heart disease (ACHD) 
on NOACs for the prevention of thromboembolism. All 
individual participants gave informed consent in accord-
ance with national and local regulations. Through collab-
oration with the International Society for Adult Congenital 
Heart Disease, patients were recruited from April 2014 in 
35 centres from 10 countries distributed over various conti-
nents including Europe, North America, Middle East and 
East Asia. The patients were included as they presented at 
the participating institutions or were identified by using a 
national registry. From the NOTE registry, all consecutive 
Fontan patients were identified and included. At baseline 
and follow-up, anatomic and clinical data including the 
details on anticoagulation use were collected. VKA-experi-
enced group and aspirin-experienced group consisted of 
the patients who used VKA or aspirin at the time of transi-
tioning to NOAC, respectively. Prospective follow-up took 
place at 6 months or/and 1 year, and 2 years, coinciding 
with their routine outpatient clinical visit or telephone 
contact. At such follow-up point, evaluation for predefined 
end points was conducted by an investigator or a site coor-
dinator, who was trained on the protocol of the NOTE 
registry.
data management
We collected patient data in an electronic case report 
form (eCRF) and submitted on a secure website, which 
is certified for Good Clinical Practice. We assigned all 
patients with a unique study identifier so that personal 
identifiable data could be removed at the hospital source, 
ensuring anonymity and protecting confidentiality. The 
principle registry coordinator and each site coordinator 
examined the completeness and accuracy of the eCRFs. 
The principle registry coordinator as an author had full 
access to all the data in the study and takes responsibility 
for its integrity and the data analysis.
study outcomes
The primary endpoints were thromboembolism 
(ischaemic cerebrovascular accident, transient ischaemic 
attack, systemic or pulmonary embolism or intracardiac 
thrombosis) and major bleeding (significant bleeding 
necessitating hospitalisation/interventions/≥2 units 
of packed cells and/or with a haemoglobin drop >1.24 
mmol/L (20g/L) and/or bleeding that was fatal or 
occurred in the following critical sites: intracranial, 
intraspinal, intraocular, pericardial, intra-articular, intra-
muscular with compartment syndrome) according to 
the International Society on Thrombosis and Haemo-
stasis criteria.9 Secondary endpoint was minor bleeding, 
defined as any bleeding that could not be classified as 
major bleeding.
statistical analysis
Descriptive statistics were used to delineate baseline char-
acteristics. Incidence rates of the outcomes were calcu-
lated using Poisson regression. Kaplan-Meier survival 
curves were created to determine event-free survival. Simi-
larly, incidence rates and event-free survival under VKA 
or aspirin treatment were determined using the histor-
ical data of VKA-experienced and aspirin-experienced 
patients for reference. Results are presented as mean 
with SD (±), median with IQR and incidence rates with 
95% CIs where appropriate. Analyses were performed 
using R V.3.2.4 (R core team) and SPSS V.23 (IBM).
Results
From April 2014 onward, 74 patients (mean age 32±10 years 
(range 18–68), 54% male) with a Fontan circulation were 
identified from 513 ACHD on NOACs (anabaptist, n=27; 
dabigatran, n=7; edoxaban, n=4; rivaroxaban, n=36) in the 
NOTE registry (table 1). The indication for NOACs was AA 
in 52 patients, primary prevention of thromboembolism 
in 12 patients and secondary prevention of thromboem-
bolism in 10 patients. CHA2DS2-VASc score was ≥1 in 49 
patients (66%) and only 2 patients had a high HAS-BLED 
(bleeding risk factor scoring system in which 1 point is 
given for uncontrolled hypertension, abnormal renal or 
liver function, history of stroke or bleeding, labile interna-
tional normalized ratio, age>65 years, use of nonsteroidal 
anti-inflammatory drug or antiplatelet agents or alcohol) 
score of t3.
During a mean follow-up of 1.4±0.9 years (total follow-up 
period 102.4 patient-years), in total, three thromboem-
bolic events (two pulmonary embolisms, one ischaemic 
stroke; annual incidence 2.9% (95% CI 0.7% to 7.6%)), 
and three major bleedings (two menorrhagia, one major 
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Table 1 Baseline characteristics of adults with 
Fontan circulation using non-vitamin K antagonist oral 
anticoagulants (NOACs)
All (n=74)
Age at inclusion, year 32±10
Male, n (%) 40 (54)
Congenital heart defect, n (%)  
  Tricuspid atresia 27 (36)
  Pulmonary atresia 10 (14)
  Double outlet right ventricle 11 (15)
  Double inlet left ventricle 14 (19)
  Other anomalies 12 (16)
Type of Fontan, n (%)  
  Atriopulmonary 26 (35)
  Total cavopulmonary connexion 48 (65)
Previous antithrombotic medication, n (%)  
  None 18 (24)
  Vitamin K antagonist 37 (50)
  Aspirin 19 (26)
Indication for NOAC, n (%)  
  Atrial arrhythmias 52 (70)
  Primary thrombotic prophylaxis 12 (16)
  Secondary thrombotic prophylaxis 10 (14)
  Median CHA2DS2-VASc 1 (0–2)
  Median HASBLED 0 (0–1)
Cardiovascular history, n (%)  
  Stroke or transient ischaemic attack (TIA) 8 (11)
  Pulmonary embolism 4 (5)
  Deep venous thrombosis 1 (1)
  Intracardiac thrombosis 7 (9)
  Inferior vena cava thrombosis 4 (5)
  Superior vena cava thrombosis 1 (1)
Values are presented as mean (±), median (IQR) or counts (%).
CHA2DS2-VASc, stroke risk factor scoring system in which 1 point 
is given for heart failure, hypertension, age 64–74 years, diabetes 
mellitus, history of vascular disease, female sex and 2 points are 
given for age ≥75 years, history of stroke/TIA/thromboembolism; 
HASBLED, bleeding risk factor scoring system in which 1 
point is given for uncontrolled hypertension, abnormal renal or 
liver function, history of stroke or bleeding, labile international 
normalised ratio, age >65 years, use of nonsteroidal anti-
inflammatory drug or antiplatelet agents or alcohol.
Figure 1 (A) Kaplan-Meier curves for survival free from 
thromboembolic event, major bleeding and minor bleeding 
in adult Fontan patients using NOACs. Nr, number. (B). 
Kaplan-Meier estimates of thromboembolic event and major 
bleeding in adult Fontan patients using VKA during 3.5 years, 
previous to NOACs use. NOAC, non-vitamin K antagonist 
oral anticoagulant; VKA, vitamin K antagonist.
Table 2 All bleeding events under non-vitamin K 
antagonist oral anticoagulants
Type of bleeding, n (%) All patients (n=74)
Major bleeding
  Total 3
  Menorrhagia 2
  Gastrointestinal bleeding 1
Minor bleeding
  Total 15
  Menorrhagia 6
  Skin haematoma 3
  Epistaxis 2
  Bleeding leading to change in antithrombotic 
therapy
2
  Prolonged bleeding after minor cut 1
  Gingival bleeding 1
gastrointestinal bleeding; annual incidence 2.9% (95% CI 
0.7% to 7.6%)) occurred in five atriopulmonary Fontan 
patients and one total cavopulmonary connection Fontan 
patient, all with AA (figure 1A, table 2). Fifteen patients 
experienced a minor bleeding (annual incidence 15.8% 
(95% CI 9.1% to 25.2%)) (figure 1A, table 2). During 
follow-up, two patients died, one due to heart failure and 
one due to cancer. In total, 14 patients ceased NOACs and 
resumed on VKAs due to thromboembolic event (n=3), 
bleeding (n=4), side effects (vasculitis, headache, n=2), 
pregnancy (n=2), patient refusal (n=2) and 1 following 
Fontan conversion. A subgroup of patients, who had no 
antithrombotic medication prior to starting NOACs and 
used NOACs for primary prevention of thromboembolism 
(n=4), did not experience any thromboembolic event or 
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major bleeding during follow-up. From this subgroup, one 
patient experienced minor bleeding (menorrhagia).
Prior to the initiation of NOAC, 50% (n=37) of the 
patients used VKAs, 26% (n=19) aspirin and 24% (n=18) 
no antithrombotic medication. During a period of 3.5 years 
prior to NOAC initiation, annual incidence of historical 
thromboembolic events and major bleeding were 2.4% 
(95% CI 0.4% to 7.4%) (n=2) and 1.2% (95% CI 0.7% to 
5.1%) (n=1), respectively, in patients previously using VKAs 
(n=37) (figure 1B). In patients previously using aspirin 
(n=19), annual incidence of historical thromboembolic 
events and major bleeding were 6.2% (95% CI 1.9% to 
14.4%) (n=4) and 0% (95% CI 0% to 0%) (n=0), respec-
tively. The incidence of minor bleeding under the histor-
ical use of VKAs and aspirin could not reliably be retrieved 
from the medical files retrospectively.
dIsCussIon
This is the first study to prospectively evaluate data on safety 
of NOACs in 70 adults with a Fontan circulation included 
in a worldwide setting. We demonstrate an annual inci-
dence of 2.9% thromboembolism, 2.9% major bleeding 
and 15.8% minor bleeding in Fontan patients actively using 
NOACs.
Our results offer important insight to NOACs’ poten-
tial in thromboembolic prevention in Fontan patients. 
Although limited by study design and smaller number 
of participants, a retrospective study in 21 adult Fontan 
patients (12 with AA) showed few adverse events (1 throm-
boembolic event, no major bleeding, median follow-up 13 
months) and therefore also did not raise safety concerns in 
using NOACs in Fontan adults in short term.10 In contrast 
with NOACs, many retrospective studies have investigated 
thromboembolic event and to a much smaller extent major 
bleeding in Fontan patients using VKAs or antiplatelet 
therapy.11 However, most of these studies were done in 
mixed cohort of paediatric and adult patients and did 
not clearly present the annual rates of thromboembolic 
and major bleeding events for comparison. One recently 
published retrospective study by Faircloth et al showed 
annual incidence of 1.9% thromboembolism, 3.8% major 
bleeding and 30.2% minor bleeding in 45 Fontan patients 
(median age 19 years, 29% AA) using VKAs for 19 months.4 
Only two recently published retrospective studies by Egbe 
et al determined thromboembolic and major bleeding 
events specifically in adult Fontan population using anti-
thrombotic therapy.3 4 One of his studies showed an annual 
incidence of 5.2% thromboembolic event in 387 adult 
Fontan cohort (mean age 28 years, 72% AA) largely using 
aspirin (85%) or warfarin (14%) with mean follow-up of 8 
years.12 Unfortunately, major bleeding (8 events including 
2 intracranial haemorrhage) and minor bleeding events 
(21 events) were not reported as incidence rates to be 
compared with our cohort using NOACs. Egbe et al’s other 
study showed annual incidence of 6.5% thromboembolism 
and 0.4% major bleeding in 278 adult Fontan cohort with 
AA (mean age 31 years) largely using antiplatelet therapy 
(65%) or anticoagulation therapy (33%, of which 97% 
warfarin, 3% rivaroxaban), of which 64% used additional 
antiplatelet therapy.2 As illustrated, it remains challenging 
to compare our results to previous studies in adult Fontan 
population since event rates are not always reported per 
antithrombotic therapy group. Therefore, we additionally 
determined the event rates with the historical data of the 
NOTE patients for comparison. When compared with the 
historical data of the NOTE patients, previously using VKAs 
(2.4% for thromboembolism, 1.2% major bleeding), use of 
NOACs in adult Fontan patients results in similar rate of 
thromboembolism and major bleeding.
Compared with historical use of aspirin (6.2% for throm-
boembolism, 0% major bleeding), not surprisingly, throm-
boembolic event rate is lower and major bleeding rate is 
higher in our cohort. In summary, based on the compar-
ison with the previous literature (1.9%–6.5% thrombo-
embolism, 0.4%–3.8% major bleeding, 30.2% minor 
bleeding) and the historical data of this cohort (2.4% for 
thromboembolism, 0.8% major bleeding), the event rates 
under NOACs use (2.9% thromboembolism, 2.9% major 
bleeding, 15.8% minor bleeding) indicate that NOACs are 
safe at this short-term observation in Fontan patients.
Although earlier studies have shown that VKAs and 
aspirin reduce the rates of thromboembolism in Fontan 
patients, each has important limitations. For example, 
VKAs bear various disadvantages including interaction with 
many drugs, intercurrent illness and therapy non-compli-
ance, which all have been associated with subtherapeutic or 
supratherapeutic INRs in Fontan patients.4 Furthermore, 
subtherapeutic INRs in Fontan patients have been shown 
to increase incidence of thromboembolism by 3.5–5.9 
times compared with Fontan patients maintained in the 
therapeutic range.13 Furthermore, it is apparent from clin-
ical practice that the cardiac lesion is not the only major 
problem for these patients, but also other issues such 
as the burden of medication use in their daily lives. The 
need for frequent monitoring interferes with these young 
patients’ social and working life, in addition to the possible 
stress caused by the daily variation in dose and the uncer-
tainty if the INR is not in the correct range. Antiplatelet 
therapy does not have such limitations, but whether it 
has the optimal efficacy to prevent thromboembolism in 
Fontan patients is yet to be determined since the results on 
its efficacy varies among the studies, some showing same 
efficacy as warfarin,5 6 but also some showing inferior effi-
cacy compared with warfarin.2 Also, it should be taken into 
account that one study observed 52% of aspirin-treated 
Fontan adults showing aspirin resistance, further ques-
tioning the practical implementation of aspirin in Fontan 
adults.5 Therefore, NOACs may be great alternatives to 
overcome limitations of VKAs and antiplatelet therapy if 
met with similar efficacy and safety on long term. However, 
one has to keep in mind that lack of INR monitoring in 
this predominantly young patients may lead to problems 
in adherence to NOACs on long term. Nonetheless, adher-
ence data from the real-world studies in the general popula-
tion with AA do show similar or even better adherence rates 
with NOACs than in VKA patients.14 Given the prospect of 
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long-term use of thromboprophylaxis in adults with Fontan 
circulation, prescribers should always be aware of the risk of 
non-persistence and adverse effects of therapy and evaluate 
these issues at every follow-up.
Our study is limited by the heterogeneity of indications 
for NOAC use, confounding by indication, modest sample 
size, limited number of events over a relatively short-term 
follow-up, and the retrospective and observational designs. 
Furthermore, our rate of thromboembolism may be under-
estimated as subclinical thromboembolism may be missed 
due to lack of additional diagnostics such as ventilation–
perfusion scan or CT at follow-up. Although half of this 
cohort used VKA previously, discrepancy in baseline charac-
teristics with the other half, who did not use VKA previously, 
may limit the comparability of incidence rates in thrombo-
embolism and major bleeding. Nonetheless, this worldwide 
study does provide the first promising evidence of efficacy 
and safety of NOACs in adults with Fontan circulation 
and offers solution to common research limitations (eg, 
inherent small sample size, retrospective design) in Fontan 
patients through international multicentre collaboration.
ConClusIons
In conclusion, NOACs are well tolerated and their efficacy 
and safety during short-term follow-up seem to be compa-
rable to use of VKAs in adults with Fontan circulation. 
Longer term data are required to confirm such promising 
early results.
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